Catabasis Pharmaceuticals Inc: Rare disease pipeline; Top-line results expected 2020 from ongoing Ph 3 trial of Edasalonexent in in DMD regardless of mutation type. North Star Ambulatory Assessment as primary endpt based on Ph 2 results and FDA input.
Based in...
US - New England
Clinical Stage
Phase III
Disease Space
Rare Disease
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Platform Technology, Small Molecule
One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, MA 02139
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Catabasis Pharmaceuticals Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Federated Global Investment Management Corp. 26.24 3,047,800 20.36 13F 2020-03-31
Altium Capital Management LP 7.96 925,000 6.18 Stakes 2019-12-31
The Vanguard Group, Inc. 5.82 675,858 4.51 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 5.77 670,526 4.48 13F 2020-03-31
Corriente Advisors LLC 5.31 617,084 4.12 Stakes 2019-12-31
Stonepine Capital Management LLC 3.36 390,000 2.61 Stakes 2019-12-31
Samsara Biocapital LLC 2.58 300,000 2.00 13F 2020-03-31
SV Health Investors LLC 2.46 285,765 1.91 13F 2020-03-31
Dimensional Fund Advisors LP 2.12 245,974 1.64 13F 2020-03-31
Clarus Ventures LLC 1.73 200,819 1.34 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.